Pharmaceutical

BNT-325 by Duality Biologics (Shanghai) for Metastatic Ovarian Cancer: Likelihood of Approval

BNT-325 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Metastatic Ovarian Cancer.

Jul 6, 2024 - 04:00
BNT-325 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Metastatic Ovarian Cancer.
Read the original article

Tags:

Previous Article

CTX-310 by CRISPR Therapeutics for Hypertriglyceridemia: Likelihood of Approval

Next Article

Hexagonal perovskite oxides: Electrolytes for next-generation protonic ceramic f...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Vanda acquires rights to Actelion’s multiple sclerosis drug

Vanda acquires rights to Actelion’s multiple sclerosis ...

Dec 8, 2023

J&J-backed Bright Peak secures $90m to advance immunoconjugate programme

J&J-backed Bright Peak secures $90m to advance immunoco...

Jun 12, 2024

Suicide hotlines shared data with Facebook, providers debate AI disclosure, and Uber Health expands

Suicide hotlines shared data with Facebook, providers d...

Jun 14, 2023